Skip to content

Advanced MR Imaging of Osteoarthritis

Advanced MR Imaging of Osteoarthritis

Status
Completed
Phases
Unknown
Study type
Observational
Source
ClinicalTrials.gov
Registry ID
NCT02883907
Acronym
AMROA
Enrollment
20
Registered
2016-08-30
Start date
2017-04-27
Completion date
2018-11-01
Last updated
2019-01-15

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Osteoarthritis

Brief summary

The utility of conventional imaging in the development of new treatments for osteoarthritis (OA) is hindered by: 1. Difficulty in non-invasively evaluating the initial response to potential new treatment options. OA typically develops over a long time period, so evaluating the efficacy of new treatment options over a timeframe relevant to experimental medicine studies is difficult. 2. Inadequate methods of disease quantification and stratification. OA is a heterogeneous condition and identifying which subgroups of patients are most likely to benefit from new treatments is crucial. Novel magnetic resonance (MR) imaging acquisition and analysis techniques have the potential to solve these problems. However, their reliability needs to be fully established and knowledge of likely effect sizes is required to inform sample size considerations for further longitudinal/interventional studies. This study aims to help address these issues by: 1. Calculating effect sizes for MR measurements to inform sample size calculations for future studies. 2. Assessing the reliability of a multiparametric MR protocol for assessment of the knee joint. The investigators will examine a single knee of an initial 15 participants with MR. Participants will be drawn from two groups: (1) 10 participants aged 40-60 years old with clinical and x-ray features of OA and (2) 5 control subjects (matched to cases for age, sex and body mass index in a 1:2 ratio) who do not have clinical features of OA. Participants will undergo an initial (baseline) MR examination, followed by repeat MR examinations at approximately 1 month and 1 year following the baseline examination. This will allow us to assess both the reliability of our MR measurements and the expected progression in our MR measurements in OA subjects in the absence of any disease-modifying intervention.

Interventions

None listed

Sponsors

Cambridge University Hospitals NHS Foundation Trust
Lead SponsorOTHER

Study design

Observational model
CASE_CONTROL
Time perspective
PROSPECTIVE

Eligibility

Sex/Gender
ALL
Age
40 Years to 60 Years
Healthy volunteers
Yes

Inclusion criteria

Group 1 Inclusion Criteria: * Meets American College of Rheumatology (ACR) criteria for OA * Kellgren-Lawrence grade 2-3 OA on knee radiograph * Medial compartment predominant disease * Neutral alignment * Aged 40-60 * Body Mass Index (BMI) \< 35 kg per square meter * Ambulatory and in good general health Group 2 Inclusion Criteria: * No current symptoms of knee pain or stiffness or other clinical features of OA * Aged 40-60 * BMI \< 35 kg per square meter * Ambulatory and in good general health

Exclusion criteria

(both groups): * History of ipsilateral lower limb fracture * History of ipsilateral lower limb surgery (including arthroscopy) * Metabolic bone disease * Inflammatory arthritis * Haematological malignancy * Paget's disease * Bone metastases * Contraindication to MR imaging (e.g. pacemaker, severe claustrophobia) * Contraindication to intravenous gadolinium based contrast medium administration (see 'Ethical Considerations' section) * Unable to consent

Design outcomes

Primary

MeasureTime frameDescription
Mean cartilage T1rho relaxation time (milliseconds)1 year
Mean cartilage T2 relaxation time (milliseconds)1 year
Mean cartilage T1 relaxation time post gadolinium (milliseconds)1 yearDerived from delayed gadolinium enhanced MR of cartilage (dGEMRIC)

Secondary

MeasureTime frameDescription
Dynamic contrast enhanced (DCE) quantitation of parameters1 yearMultiple DCE parameters calculated allowing description of enhancement rate and pattern of synovium
Modified Osteoarthritis Knee Score (MOAKS) (arbitrary units)1 yearSemiquantitative scoring system
Osteochondral junction integrity (semiquantitative grading, arbitrary units)1 year
Subchondral bone texture index (arbitrary units)1 year
Cartilage thickness values (millimeters)1 yearSurface-based comparison using statistical parametric mapping
Subchondral bone area (millimeters squared)1 year

Countries

United Kingdom

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026